<DOC>
	<DOCNO>NCT02036957</DOCNO>
	<brief_summary>Capecitabine drug produce dermatologic toxicity frequently ( palmoplantar erythrodysesthesia , rash , alopecia , erythema , dryness , pruritus , hyperpigmentation , rash , peeling , dermatitis , abnormal pigmentation , less often blister , skin ulcer , photosensitivity reaction , swell face purple ) . The impact patient ' quality life great , We decide conduct randomize clinical trial evaluate effectiveness Mary D ' uol balm prevent dermatologic toxicity patient treat capecitabine . Design : Randomized clinical trial phase II , parallel double-blind group Target population : Patients colon cancer stage II III ( Dukes ' C ) , initiate treatment capecitabine monotherapy . Inclusion criterion : Over 18 year , II III colon ( Dukes ' C ) colon cancer , primary diagnosis , capecitabine monotherapy , sign inform consent . Primary endpoint : Dermatologic toxicity ( yes / ) Statistical analysis : The primary endpoint ( percentage patient develop dermalogic toxocity group ) analyze logistics regression model</brief_summary>
	<brief_title>MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS ' SKIN TOXICITY</brief_title>
	<detailed_description>Intervention : Preventive treatment dermatologic toxicity begin day initiation treatment Xeloda , capecitabine + oxaliplatin , Adriamycin Liposomial cytarabine The product apply throughout body abundant quantity skin perfectly hydrate . It apply twice daily ( shower evening ) , gently massage area completely absorb . The product provide unit oncology pharmacy , patient randomize . 3 pack per cycle provide . If enough ( patient great surface area ) supply . Each time start new cycle 3 new package deliver . The patient apply cosmetic product treat area . In addition patient regardless group receive recommendation reduce appearance skin problem cause type drug . The study total duration 24 week ( 8 cycle chemotherapy ) , except case patient require cycle delay filing toxicity . In patient total duration study must sufficient end eighth cycle . If side effect severe greatly affect quality life patient doctor think fit , may prescribe drug treatment .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Drug Eruptions</mesh_term>
	<criteria>Over 18 year . Sign informed consent Patients neoadjuvant treatment . Patients dermatologic disease . Patients treated corticosteroid .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>dermatologic toxicity</keyword>
</DOC>